Abstract:Db/db mice exhibited low vagal activity and diabetic myocardial injury, accompanied by gut microbiota dysbiosis and gut barrier dysfunction, as well as increased lipopolysaccharide (LPS) concentrations and metabolic inflammation. Importantly, pyridostigmine could protect against diabetic myocardial injury by alleviating gut microbiota dysbiosis and gut barrier dysfunction and reducing metabolic inflammation, possibly by inhibiting the LPS‐induced activation of the ERK/Egr‐1 pathway. Moreover, acetylcholine ameliorated high‐glucose (HG) and LPS‐induced cardiomyocytes injury by inhibiting the ERK/Egr‐1 pathway and inflammation through α7nAChR. Autonomic imbalance and metabolic inflammation are important pathological processes in diabetic cardiomyopathy. Gut microbiota dysbiosis and increased levels of bacterial component lipopolysaccharide (LPS) are associated with diabetic myocardial injury, but the mechanism by which gut microbes affect metabolic inflammation and cardiac injury remains unclear. We determined whether pyridostigmine (PYR), which inhibits cholinesterase to improve vagal activity, could regulate the disordered gut microbiota and attenuate gut barrier dysfunction, metabolic endotoxemia, and inflammation in diabetes. Db/db mice exhibited high blood glucose levels, insulin resistance, low vagal activity, and diabetic myocardial injury. Db/db mice also exhibited gut microbiota perturbations and subsequent disruption of gut barrier function, resulting in an influx of LPS, metabolic endotoxemia, and inflammation. PYR ameliorated the dysregulated glucose and lipid metabolism, modulated the overall structure of the gut microbiota, selectively enhanced the abundance of anti‐inflammatory bacteria, and reduced the abundance of proinflammatory and potentially pathogenic bacteria in db/db mice. Importantly, PYR enhanced vagal activity, restored gut microbiota homeostasis, and alleviated gut barrier dysfunction. Therefore, the LPS‐induced extracellular signal‐regulated kinase (ERK)/early growth response‐1 (Egr‐1) pathway and consequent metabolic inflammation were inhibited, and eventually, cardiac hypertrophy, fibrosis, oxidative stress, and dysfunction were ameliorated in db/db mice. In vitro cardiomyocyte injury was induced by exposing primary neonatal rat ventricular cardiomyocytes to high glucose (HG) and LPS. In vitro analyses showed that HG + LPS induced ERK1/2 phosphorylation, Egr‐1 expression, inflammation, and cell apoptosis, which were inhibited by acetylcholine (ACh). Alpha 7 nicotinic ACh receptor but not muscarinic 2 ACh receptor plays an important role in ACh‐mediated anti‐inflammatory effects and inhibiting the ERK/Egr‐1 pathway in HG + LPS‐administered neonatal rat ventricular cardiomyocytes. PYR and ACh ameliorated diabetic myocardial injury by inhibiting the LPS‐induced ERK/Egr‐1 pathway and metabolic inflammation. The vagus–gut–heart axis has provided new insights into the complex mechanisms of diabetes and offers novel therapeutic targets.

Pyridostigmine Exerts Cardiovascular Protection Effects Via Ameliorating Damaged Mitochondrial Cristae in High Fat Diet-Induced Obese Mice

Pyridostigmine Alleviates Cardiac Dysfunction Via Improving Mitochondrial Cristae Shape in a Mouse Model of Metabolic Syndrome.

Pyridostigmine Protects Against Cardiomyopathy Associated with Adipose Tissue Browning and Improvement of Vagal Activity in High-Fat Diet Rats.

Metabolomic and transcriptomic studies of improvements in myocardial infarction due to Pycr1 deletion

Pyridostigmine attenuated high‐fat‐diet induced liver injury by the reduction of mitochondrial damage and oxidative stress via α7nAChR and M3AChR

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Gut Microbiota and Branched-Chain Amino Acid Catabolism to Attenuate Mitochondria Dysfunction

Pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice.

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice

Effects of Augmented Delivery of Pyruvate on Myocardial High-Energy Phosphate Metabolism at High Workstate

Regulation of Mitochondrial Cristae Remodelling by Acetylcholine Alleviates Palmitate-Induced Cardiomyocyte Hypertrophy

Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells

Recent Progress on Obesity-Induced Myocardial Remodeling and Its Possible Mechanism of Mitochondrial Dyshomeostasis

Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK/Egr‐1 pathway

Exercise enhances cardiac function by improving mitochondrial dysfunction and maintaining energy homoeostasis in the development of diabetic cardiomyopathy

Pyridostigmine Ameliorates Cardiac Remodeling Induced by Myocardial Infarction Via Inhibition of the Transforming Growth Factor-β1/TGF-β1–Activated Kinase Pathway

Mitochondrial Dynamic Remodeling In Strenuous Exercise-Induced Muscle And Rnitochondrial Dysfunction: Regulatory Effects Of Hydroxytyrosol

High fat diet ameliorates mitochondrial cardiomyopathy in CHCHD10 mutant mice

Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.

Pyridostigmine Prevents Peripheral Vascular Endothelial Dysfunction in Rats with Myocardial Infarction

The Crosstalk between Cardiac Lipotoxicity and Mitochondrial Oxidative Stress in the Cardiac Alterations in Diet-Induced Obesity in Rats

Endurance exercise preconditioning alleviates ferroptosis induced by doxorubicin-induced cardiotoxicity through mitochondrial superoxide-dependent AMPKα2 activation